Benaroya Research Institute

What Benaroya Research Institute does

Benaroya Research Institute (BRI) is a Seattle-based 501(c)(3) nonprofit research institute, founded in 1956 and affiliated with Virginia Mason Franciscan Health, that operates as a dedicated human immunology research organization. Its mission is to predict, prevent, reverse, and cure diseases of the immune system, with a primary focus on autoimmune conditions such as type 1 diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, and celiac disease. BRI serves multiple stakeholder groups: patients who enroll in clinical studies and biorepository programs, academic and clinical collaborators, biotech and pharmaceutical partners, and federal/private funders.

BRI's core technical platform is built around four Centers of Discovery (Fundamental, Translational, Interventional, and Systems Immunology), four Core Labs (Cell and Tissue Analysis, Genomics, Human Immunophenotyping, Protein and Tetramer), and eleven biorepositories holding hundreds of thousands of biological samples. Differentiated technologies include FOXP3/Treg biology leadership, DNA-barcoded HLA class II tetramers, single-cell CRISPR screening with AAV vectors, massively parallel reporter assays for noncoding variant screening, autoantibody screening assays, and the EngTreg (engineered regulatory T-cell) platform that underpins GNTI-122, which entered a Phase 1 POLARIS clinical trial in January 2026 for type 1 diabetes. BRI also hosts the Immune Tolerance Network research consortium.

BRI's revenue model is donation- and grant-driven rather than product-commercial. Primary funding comes from NIH research grants (R01, UM1, U01, R21) at a run rate suggesting $50–70M+ annually, supplemented by private foundation grants (notably the Fund for Science and Technology backed by the Paul G. Allen estate, Helmsley Charitable Trust, Breakthrough T1D/JDRF), industry collaboration funding (e.g., GentiBio for GNTI-122), and individual philanthropy routed through the Virginia Mason Foundation. Technology licensing to biotech and pharma partners (tetramer reagents, EngTreg platform) is a secondary commercialization pathway. BRI does not sell commercial products and provides research participation at no cost to eligible participants.

Name

Benaroya Research Institute

Legal name

Benaroya Research Institute

Website

https://benaroyaresearch.org

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

Benaroya Research Institute is a Seattle-based nonprofit research institute affiliated with Virginia Mason Franciscan Health, dedicated to predicting, preventing, and curing autoimmune and immune system diseases through translational human immunology research, biorepositories, and engineered Treg cell therapy development.

Ownership category

akta.pro rank

Product category

Medical Research Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Immunology research services
• Autoimmune disease research
• Clinical immunology trials
• Biorepository research services
• Translational immunology research

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. NIH Research Grants: Primary funding source from National Institutes of Health, including R01 grants, UM1 grants, U01 grants, and R21 grants supporting various immunology and autoimmune disease research projects
2. Private Foundation Grants: Funding from private foundations including the Fund for Science and Technology (FFST) backed by Paul G. Allen's estate, Helmsley Charitable Trust, and others
3. Industry Collaboration Funding: Funding and support from biotech and pharmaceutical partnerships including Breakthrough T1D/JDRF, University of Colorado, and clinical trial collaborations
4. Donations and Philanthropy: Charitable donations from individuals supporting research activities, including the Innovation Fund for pilot projects

Distribution channels4 records

Marketing channels8 records

Core offering

Benaroya Research Institute (BRI) is a nonprofit research institute that conducts human immunology research aimed at predicting, preventing, reversing and curing diseases of the immune system. It operates Core Labs (genomics, immunophenotyping, tetramer), eleven Biorepositories, four Centers of Discovery (Fundamental, Translational, Interventional, and Systems Immunology), clinical research programs, and collaborative clinical-stage therapies such as GNTI-122 for type 1 diabetes.

Product overview

Benaroya Research Institute (BRI) is a nonprofit research institute focused on advancing science to predict, prevent, reverse and cure diseases of the immune system. BRI operates as a research organization with multiple interconnected programs rather than a commercial product company. The institute offers research services through Core Labs (Cell and Tissue Analysis, Genomics, Human Immunophenotyping, Protein and Tetramer), maintains eleven Biorepositories for biological samples, and conducts research through four Centers of Discovery (Fundamental, Translational, Interventional, and Systems Immunology). Educational resources include an Immunology Learning Center and Autoimmune Life Blog. BRI collaborates on clinical stage therapies including GNTI-122 for type 1 diabetes and conducts longitudinal research programs like the Sound Life Project studying healthy immune systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Core Labs
• Biorepositories
• Centers of Discovery
• Clinical Research
• Sound Life Project
• GNTI-122 EngTreg Therapy

Quantifiable outcome

• Discovery of FOXP3 gene (1995) led to revolutionary understanding that immune tolerance is not static but can be changed throughout life
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and major.

• Seattle Children's Research InstitutecoreStrategic or Co-development Partner · 22 April 2026Long-standing scientific collaboration supporting development of GNTI-122 engineered Treg therapy into Phase 1 clinical trials (POLARIS study) for type 1 diabetes. The collaboration brings together foundational discoveries from David Rawlings' lab (SCRI) on Treg generation methods with BRI's T cell receptor expertise.
• GentiBiocoreStrategic or Co-development Partner · 22 April 2026Biotechnology partnership advancing GNTI-122, an engineered regulatory T cell therapy for type 1 diabetes. GentiBio provides leadership in cell engineering, translational development, manufacturing and clinical execution. The therapy combines three technological pillars: FOXP3 expression, CISC signaling, and BRI's T1D-specific TCR.
• Allen Institute for ImmunologycoreStrategic or Co-development Partner · 20 December 2019Research partnership led by the Allen Institute for Immunology, with BRI providing detailed information about healthy immune systems as a foundation for disease research programs. The Sound Life Project investigates immune system variation in 100 healthy individuals over two years.
• Fred Hutchinson Cancer Research CentermajorStrategic or Co-development Partner · 20 December 2019Partner in the Sound Life Project studying healthy immune systems, contributing to the multi-institutional research initiative on immunology and aging.
• University of California San DiegomajorStrategic or Co-development Partner · 20 December 2019Academic partner in the Sound Life Project investigating healthy immune system variation and aging research.
• University of Colorado Anschutz Medical CampusmajorStrategic or Co-development Partner · 20 December 2019Academic partner in the Sound Life Project studying healthy immune systems across different age groups.
• University of PennsylvaniamajorStrategic or Co-development Partner · 20 December 2019Academic partner in the Sound Life Project contributing to the understanding of healthy immune system variation.
• Virginia Mason Franciscan HealthcoreStrategic or Co-development PartnerBRI is affiliated with Virginia Mason Franciscan Health, enabling integration of laboratory research with clinical care. BRI researchers practice at Virginia Mason Medical Center, and clinical trials are conducted at VMMC facilities.
• Immune Tolerance NetworkmajorStrategic or Co-development PartnerBRI hosts the Immune Tolerance Network, a research consortium focused on developing new therapies that switch off harmful immune responses without compromising the body's ability to fight disease.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Allen Institute for Immunology: Seattle-based nonprofit research organization focused on human immune system research. Direct partner of BRI on the Sound Life Project, with overlapping focus on healthy baseline immunology and systems-level immune profiling.
• La Jolla Institute for Immunology: Nonprofit immunology research institute with a comparable mission in fundamental and translational immunology, biorepository operations, and academic-industry partnerships targeting autoimmune disease and infectious disease.
• Seattle Children's Research Institute: Pediatric-focused research institute and core BRI partner on the GNTI-122 EngTreg program, with overlapping translational immunology research, biorepository infrastructure, and clinical trial execution capabilities.
• Fred Hutchinson Cancer Center: Seattle-based nonprofit biomedical research institute with overlapping immunology, cell therapy, and clinical trial infrastructure. Sound Life Project partner, sharing both geographic ecosystem and translational research model.
• Immune Tolerance Network: NIH-funded research consortium hosted at BRI, focused on developing therapies that switch off harmful immune responses. Operates within BRI's footprint and shares its therapeutic tolerance and autoimmune disease mission.
• National Jewish Health: Nonprofit academic medical center specializing in respiratory, allergic, and immune system diseases. Comparable model as a research-driven specialty institution focused on immunology, with clinical trial and biorepository infrastructure.
• Oklahoma Medical Research Foundation: Independent nonprofit biomedical research institute with significant autoimmune disease research programs, biorepository operations, and clinical trial infrastructure. Comparable operating model as a standalone immunology-focused research nonprofit.

Broad incumbents

• Massachusetts General Hospital Immunology / MGH Center for Immunology: Major academic medical center with a dedicated immunology research program covering autoimmune disease and translational research. Larger and more diversified portfolio, but overlapping research areas with BRI's translational immunology focus.
• Stanford University School of Medicine - Department of Immunology and Rheumatology: Top-tier academic immunology department with comparable fundamental immunology and autoimmune disease research capabilities, including Treg biology and translational programs. Operates within a broader medical school portfolio rather than as a standalone research institute.

Emerging players

• GentiBio: Biotech developing engineered Treg therapies, with a core strategic partnership with BRI on GNTI-122 for type 1 diabetes. Comparable focus on engineered Treg cell therapy for autoimmune disease, but operates as a commercial-stage biotech rather than research institute.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/BenaroyaResearch
• Facebookfacebook.com/BenaroyaResearch
• LinkedInlinkedin.com/company/benaroya-research-institute
• Instagraminstagram.com/benaroyaresearch
• Xx.com/BRIautoimmune

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Benaroya Research Institute